Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Concert Pharmaceuticals Inc    CNCE

CONCERT PHARMACEUTICALS INC (CNCE)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/21/2018 05/22/2018 05/23/2018 05/24/2018 05/25/2018 Date
20.13(c) 20.39(c) 20.21(c) 19.96(c) 20(c) Last
90 191 108 820 86 085 114 980 81 965 Volume
-1.66% +1.29% -0.88% -1.24% +0.20% Change
More quotes
Financials (USD)
Sales 2018 10,5 M
EBIT 2018 -53,2 M
Net income 2018 -53,7 M
Finance 2018 21,3 M
Yield 2018 -
Sales 2019 10,4 M
EBIT 2019 -67,8 M
Net income 2019 -67,3 M
Finance 2019 21,2 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 42,5x
EV / Sales2019 42,8x
Capitalization 468 M
More Financials
Company
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology.Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system... 
Sector
Biotechnology & Medical Research
Calendar
06/06 | 08:00pmPresentation
More about the company
Surperformance© ratings of Concert Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on CONCERT PHARMACEUTICALS IN
05/10CONCERT PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/03CONCERT PHARMACEUTICALS : Completes Enrollment in Phase 2a Trial of CTP-543 in A..
AQ
05/03CONCERT : 1Q Earnings Snapshot
AQ
05/03CONCERT PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
05/03CONCERT PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (f..
AQ
05/03CONCERT PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
BU
04/30CONCERT PHARMACEUTICALS : to Report First Quarter 2018 Financial Results on May ..
AQ
04/30CONCERT PHARMACEUTICALS : Completes Enrollment in Phase 2a Trial of CTP-543 in A..
AQ
04/27CONCERT PHARMACEUTICALS INC : Wired News – Concert Pharma Enrolled Last Patient ..
AC
04/26CONCERT PHARMACEUTICALS : to Report First Quarter 2018 Financial Results on May ..
BU
More news
Sector news : Biotechnology & Medical Research - NEC
05/25The Heated Quest for Opioid Alternatives -2-
DJ
05/25The Heated Quest for Opioid Alternatives
DJ
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/25Zacks: Analysts Expect Concert Pharmaceuticals $CNCE to Announce -$0.62 EPS  
05/25Get the latest ratings for $ASPX $HSON $DXLG $GNCA $CNCE in your inbox with M.. 
05/24The NFL's New Anthem Policy Is Madness--But the Players Can Stop It (Robert S..
1
05/23$CNCE  
05/11Weekly Research Analysts’ Ratings Updates for Concert Pharmaceuticals $CNCE  
More tweets
Qtime:112
News from SeekingAlpha
05/23Concert Pharmaceuticals (CNCE) Presents At 2018 UBS Global Healthcare Confere.. 
05/06Concert Pharmaceuticals' (CNCE) CEO Roger Tung on Q1 2018 Results - Earnings .. 
05/04Concert Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides 
05/03Concert Pharma beats by $0.39 
04/30Vertex Hits Stumbling Block For One Triple-Combo Therapy For Cystic Fibrosis 
Chart CONCERT PHARMACEUTICALS IN
Duration : Period :
Concert Pharmaceuticals In Technical Analysis Chart | CNCE | US2060221056 | 4-Traders
Technical analysis trends CONCERT PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 28,0 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Roger D. Tung President, Chief Executive Officer & Director
Richard H. Aldrich Chairman
Nancy Stuart Chief Operating Officer
Marc Becker Chief Financial Officer
Wilfred E. Jaeger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CONCERT PHARMACEUTICALS INC-22.69%468
CELLTRION, INC.--.--%30 812
IQVIA HOLDINGS INC4.64%21 079
LONZA GROUP1.63%20 077
INCYTE CORPORATION-29.71%14 132
NEKTAR THERAPEUTICS42.83%13 799